Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27731553 | 0.79 | MEN1 (0.41) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL25308673 | 0.79 | KMT2A (0.42) | ALDH1A1KMT2AMEN1APPGAA | |
| SCHEMBL22426419 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL50746 | 0.78 | HPGD (0.50) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| Salicylic Acid SCHEMBL810750 | 0.76 | ALDH1A1 (0.70) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL5956989 | 0.75 | ALDH1A1 (0.52) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL10934521 | 0.75 | ALDH1A1 (0.52) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL5956988 | 0.75 | ALDH1A1 (0.52) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL10556740 | 0.74 | ESR1 (0.59) | ALDH1A1KDM4EKMT2AHPGDAPP | |
| SCHEMBL28363683 | 0.73 | PLOD2 (0.71) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466266-B1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | TRANSNEURAL THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | Transneural Therapeutics, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. | 2024-12-26 | — | — | US | disclosed |
| EP-4466266-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | Transneural Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459944-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | ALDH1A1 760/4885KDM4E 2039/4885L3MBTL1 4734/4885 |
| US-20250243199-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | ALDH1A1 760/4885KDM4E 2039/4885L3MBTL1 4734/4885 |
| US-20240425503-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR1A | ALDH1A1 659/4885KDM4E 1655/4885L3MBTL1 3955/4885 |
| US-12486268-B2 | Fused heterocycles as 5-HT2A receptor agonists | HTR2A, HTR2C, HTR5A | ALDH1A1 760/4885KDM4E 2039/4885L3MBTL1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.